USP and Public Policy

Left

USP Comment Letter: Submitted to FDA on Approval Pathway for Biosimilar and Interchangeable Biological Products (2010)

USP appreciates the opportunity to provide input as the Food and Drug Administration (FDA) proceeds with implementation of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). Learn More

USP White Paper: Assuring Quality in Medicines Procurement

Significant global health gains have been made in the last few decades, in part thanks to increased access to prevention, therapeutics, and services provided by government donors and global financing… Learn More

USP White Paper: Increasing Transparency in the Medicines Supply Chain

Harnessing information to inform effective action to reduce vulnerabilities and prevent or mitigate disruptions in the global supply of quality medicines. Learn More

USP White Paper: What’s Next for Compounded Medicines- Advancing Quality and Supporting Patient Access

Compounding of medicines has a longstanding history and remains an important aspect of pharmacy practice. USP compounding standards serve as an integral part of the legal and regulatory frameworks… Learn More

USP White Paper: Advancing Quality of Medicines to Combat Antimicrobial Resistance

Antimicrobial resistance (AMR) presents a catastrophic risk to human health and life around the globe. the U.S. Pharmacopeial Convention (USP) engages in global policy dialogue to advance medicines… Learn More

USP and Public Policy

Refine Your Search

Document Classification

Topics